[go: up one dir, main page]

WO2008153072A1 - 骨・関節疾患感受性遺伝子およびその用途 - Google Patents

骨・関節疾患感受性遺伝子およびその用途 Download PDF

Info

Publication number
WO2008153072A1
WO2008153072A1 PCT/JP2008/060700 JP2008060700W WO2008153072A1 WO 2008153072 A1 WO2008153072 A1 WO 2008153072A1 JP 2008060700 W JP2008060700 W JP 2008060700W WO 2008153072 A1 WO2008153072 A1 WO 2008153072A1
Authority
WO
WIPO (PCT)
Prior art keywords
joint
bone
destruction
joint disease
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060700
Other languages
English (en)
French (fr)
Inventor
Shiro Ikegawa
Hideyuki Mototani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
RIKEN
Original Assignee
Takeda Pharmaceutical Co Ltd
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, RIKEN filed Critical Takeda Pharmaceutical Co Ltd
Priority to US12/664,337 priority Critical patent/US20100239501A1/en
Priority to EP08765479A priority patent/EP2153847A4/en
Priority to JP2009519284A priority patent/JPWO2008153072A1/ja
Publication of WO2008153072A1 publication Critical patent/WO2008153072A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)

Abstract

　本発明は、配列番号: 2で表されるアミノ酸配列と同一もしくは実質的に同一のアミノ酸配列を含む蛋白質の発現もしくは活性を抑制する物質を含有してなる、関節における炎症性サイトカイン発現および／または関節破壊（例、関節軟骨破壊）および／または骨・関節疾患における疼痛の抑制剤、該蛋白質またはその部分ペプチドを用いることを特徴とする、関節における炎症性サイトカイン発現および／または関節破壊（例、関節軟骨破壊）および／または骨・関節疾患における疼痛を調節する物質のスクリーニング方法、ならびに配列番号: 3で表されるヒトEDG2遺伝子の部分塩基配列において、塩基番号24007で示される塩基における多型を検出することを含む、骨・関節疾患に対する遺伝的感受性の診断方法を提供する。
PCT/JP2008/060700 2007-06-12 2008-06-11 骨・関節疾患感受性遺伝子およびその用途 Ceased WO2008153072A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/664,337 US20100239501A1 (en) 2007-06-12 2008-06-11 Gene sensitive to bone/joint disease and use thereof
EP08765479A EP2153847A4 (en) 2007-06-12 2008-06-11 AGAINST BONE / GRAIN DISEASE SENSITIVE GENE AND USE THEREOF
JP2009519284A JPWO2008153072A1 (ja) 2007-06-12 2008-06-11 骨・関節疾患感受性遺伝子およびその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007155792 2007-06-12
JP2007-155792 2007-06-12

Publications (1)

Publication Number Publication Date
WO2008153072A1 true WO2008153072A1 (ja) 2008-12-18

Family

ID=40129677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060700 Ceased WO2008153072A1 (ja) 2007-06-12 2008-06-11 骨・関節疾患感受性遺伝子およびその用途

Country Status (4)

Country Link
US (1) US20100239501A1 (ja)
EP (1) EP2153847A4 (ja)
JP (1) JPWO2008153072A1 (ja)
WO (1) WO2008153072A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373151B1 (es) * 2010-07-16 2012-12-14 Universidade De Santiago De Compostela Uso de inhibidores de edg2 para el tratamiento de la artritis reumatoide.
CN108546753A (zh) * 2018-05-02 2018-09-18 宁波美丽人生医药生物科技发展有限公司 巴氯芬药物相关基因gabbr1基因多态性检测试剂盒
IL311184A (en) * 2021-09-02 2024-04-01 Djs Antibodies Ltd polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508135A (ja) * 1995-06-20 1999-07-21 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトｅｄｇ−２受容体ホモログ
JP2004000209A (ja) * 2002-04-26 2004-01-08 Sumitomo Pharmaceut Co Ltd 軟骨障害マーカー及びその利用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820703B2 (en) * 2004-05-06 2010-10-26 University Of Virginia Patent Foundation Lysophosphatidic acid receptor selective antagonists
JP5076058B2 (ja) * 2004-08-04 2012-11-21 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508135A (ja) * 1995-06-20 1999-07-21 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトｅｄｇ−２受容体ホモログ
JP2004000209A (ja) * 2002-04-26 2004-01-08 Sumitomo Pharmaceut Co Ltd 軟骨障害マーカー及びその利用

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BOUCHARABA A. ET AL.: "The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 25, 2006, pages 9643 - 9648, XP009093163 *
DATABASE GENBANK [online] 27 April 1999 (1999-04-27), BIRREN B. ET AL.: "Definition: Homo sapiens, clone hRPK.78_A_1, complete sequence", XP008116612, Database accession no. (AC007157) *
DUNCLIFFE K.N. ET AL.: "A T cell-specific enhancer in the interleukin-3 locus is activated cooperatively by Oct and NFAT elements within a DNase I-hypersensitive site", IMMUNITY, vol. 6, no. 2, 1997, pages 175 - 185, XP008125118 *
FAHMI H. ET AL.: "Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1", OSTEOARTHRITIS AND CARTILAGE, vol. 10, no. 2, 2002, pages 100 - 108, XP008125121 *
MACIAN F. ET AL.: "Partners in transcription: NFAT and AP-1", ONCOGENE, vol. 20, no. 19, 2001, pages 2476 - 2489, XP008125119 *
MCCARTHY G.M. ET AL.: "Molecular mechanism of basic calcium phosphate crystal-induced activation of human fibroblasts. Role of nuclear factor kappab, activator protein 1, and protein kinase c", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 52, 1998, pages 35161 - 35169, XP001539892 *
MOTOTANI H. ET AL.: "A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese", HUMAN MOLECULAR GENETICS, vol. 17, no. 12, 2008, pages 1790 - 1797, XP008125126 *
NOCHI H. ET AL.: "Effects of lysophosphatidic acid and proinflammatory cytokines on the expression of cyclooxygenase-2 in rheumatoid synovial cells", SEIKAGAKU, vol. 75, no. 8, 25 August 2003 (2003-08-25), pages 870 + ABSTR. NO. 2P-570, XP008118282 *
NOCHI H. ET AL.: "Kansetsu Katsumaku Saibo no Lysophosphatidic Acid to Sphingosine 1-phosphate no COX-2 no Hatsugen Zokyo Sayo", SEIKAGAKU, vol. 74, no. 8, 25 August 2002 (2002-08-25), pages 951 + ABSTR. NO. 3P-717, XP008118280 *
NOCHI H. ET AL.: "Kansetsu Katsumaku Saibo no Lysophospholipid ni yoru Ensho Hanno ni Oyobosu Kobunshiryo Hyaluronic Acid no Eikyo", THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 124TH, no. 4, 5 March 2004 (2004-03-05), pages 39 + ABSTR. NO. 30[P1]II-121, XP008118283 *
NOCHI H. ET AL.: "Kansetsu Rheumatism no Byotai Keisei ni Okeru Lysophospholipid no Yakuwari", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 34, 5 November 2004 (2004-11-05), pages 162 + ABSTR. NO. 2-C-W21-2-P, XP008118284 *
NOCHI H. ET AL.: "Lysophosphatidic Acid ya Sphingosine 1-phosphate wa Kansetsu Katsumaku Saibo no COX-2 Hatsugen o Zokyo suru", THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 122ND, no. 4, 5 March 2002 (2002-03-05), pages 30 + ABSTR. NO. 27[P]I-380 *
See also references of EP2153847A4 *
SUN Y. ET AL.: "Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1/metalloproteinase 1 pathway. Involvement of transcription factor binding sites AP-1 and PEA-3", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 2, 2002, pages 1544 - 1552, XP008125120 *
ZHAO C. ET AL.: "Lysophosphatidic acid and its receptors in the pathogenesis of rheumatoid arthritis", FASEB JOURNAL, vol. 20, no. 4, PART 1, 6 March 2006 (2006-03-06), pages A113, XP008125117, Retrieved from the Internet <URL:http://www.fasebj.org/cgi/content/meeting_abstract/20/4/A113-a> *
ZHAO C. ET AL.: "Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?", MOLECULAR PHARMACOLOGY, vol. 73, no. 2, February 2008 (2008-02-01), pages 587 - 600, XP008125221 *

Also Published As

Publication number Publication date
JPWO2008153072A1 (ja) 2010-08-26
EP2153847A4 (en) 2010-09-29
EP2153847A1 (en) 2010-02-17
US20100239501A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
FR23C1024I1 (fr) Composition stable d&#39;une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
EP1661909A4 (en) BIOLOGICALLY NON-DEGRADABLE PEPTIDE, INHIBITOR OF ANGIOT-INTEGRATED ENZYME, MEDICAMENT AND FUNCTIONAL FOOD
WO2008063113A8 (en) Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
IN2012DN02981A (ja)
WO2002044320A3 (en) Human elongase genes and uses thereof
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
WO2008153072A1 (ja) 骨・関節疾患感受性遺伝子およびその用途
AU2017249629B2 (en) Method for the treatment or prevention of osteoarthritis.
JP2008541776A5 (ja)
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2000005373A3 (en) Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
Pham et al. Expression analysis of nha-oc/NHA2: a novel gene selectively expressed in osteoclasts
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson&#39;s disease
WO2004027062A3 (de) Funktionelle korrektur der -786 c/t-varianz des humanen enos-gens
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
TW442494B (en) Novel, ATP-sensitive potassium-channel proteins and genes for the same
GB0426960D0 (en) TGR-3 like protein receptor
ATE513044T1 (de) Nukleotid und aminosäuresequenzen aus photobacterium damselae und deren verwendung
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2006000464A3 (de) Verfahren zum auffinden schmerzrelevanter substanzen unter verwendung schmerzrelevanter proteine
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone
TW200502398A (en) Use of peptidylarginine deiminase type IV

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765479

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009519284

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008765479

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12664337

Country of ref document: US